Abstract: A developing device includes a first chamber, a second chamber, a first inlet portion, a first carrying member and an auxiliary blade. The first chamber receives a developer supplied to a developer holder. The second chamber receives the developer carried from the first chamber after being circulated between the first chamber and the second chamber. The first inlet portion allows the developer to be introduced from the second chamber to the first chamber. The first carrying member is disposed in the first chamber to carry the developer in the first chamber in a first carrying direction. The first carrying member includes a rotating shaft, a spiral blade provided at an outer periphery of the rotating shaft, and the auxiliary blade formed toward an upstream side of the first carrying direction from the spiral blade.

Abstract: A developing device includes a first chamber, a second chamber, a first inlet portion, a first carrying member and an auxiliary blade. The first chamber receives a developer supplied to a developer holder. The second chamber receives the developer carried from the first chamber after being circulated between the first chamber and the second chamber. The first inlet portion allows the developer to be introduced from the second chamber to the first chamber. The first carrying member is disposed in the first chamber to carry the developer in the first chamber in a first carrying direction. The first carrying member includes a rotating shaft, a spiral blade provided at an outer periphery of the rotating shaft, and the auxiliary blade formed toward an upstream side of the first carrying direction from the spiral blade.

Abstract: The present invention relates to novel Aerothricins represented by the Formula (I), wherein R1, R2, R3, R4, R5, X, Y, Z, and m are as defined in Claim 1; and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition comprising an Aerothricin of the Formula (I) and a pharmaceutically acceptable carrier. Furthermore, the present invention relates to the use of such Aerothricins for the preparation of medicaments, as well as to processes and intermediates for the preparation of the Aerothricins of the Formula (I).

Abstract: Disclosed is the novel compound BU-4664L and derivatives thereof. The compound is produced by fermentation of Micromonospora sp. M990-6. The compound possesses anti-inflammatory and/or anti-tumor cell activities.

Abstract: Novel compounds derived from cultures of Streptomyces sp. AA2807 are useful as 5-lipoxygenase inhibitors.

Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.

Abstract: The present invention relates to the antitumor antibiotic compound BU-3285T and its preparation. The compound is obtained by culturing a new strain of Chainia rosea and demonstrates both antitumor and antifungal activity. It also relates to the desulfated derivative of BU-3285T which is obtained by treatment of BU-3285T with sulfatase enzyme. BU-3285T desulfate possesses antitumor activity.

Abstract: The present invention relates to the antitumor antibiotic compound BU-3285T and its preparation. The compound is obtained by culturing a new strain of Chainia rosea and demonstrates both antitumor and antifungal activity. It also relates to the desulfated derivative of BU-3285T which is obtained by treatment of BU-3285T with sulfatase enzyme. BU-3285T desulfate possesses antitumor activity.

Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.

Abstract: The present invention relates to the antitumor antibiotic compound BU-3285T and its preparation. The compound is obtained by culturing a new strain of Chainia rosea and demonstrates both antitumor and antifungal activity. It also relates to the desulfated derivative of BU-3285T which is obtained by treatment of BU-3285T with sulfatase enzyme. BU-3285T desulfate possesses antitumor activity.

Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.

Abstract: A novel antibiotic complex designated herein as BBM-1675 complex is produced by fermentation of certain novel strains of Actinomadura verrucosospora. The complex may be separated into two major components, BBM-1675 A.sub.1 and A.sub.2, and four minor components, BBM-1675 A.sub.3, A.sub.4, B.sub.1 and B.sub.2, and such components exhibit both antimicrobial activity and antitumor activity.

Abstract: There is disclosed an antibiotic complex designated as BU-2231 V which is produced by fermentation of a BU-2231-producing strain of Streptoalloteichus hindustanus, ATCC 31158. Complex BU-2231 V is recovered and purified from the fermentation broth by use of ion exchange chromatography techniques. Structural analysis shows that the complex is a mixture of components which are .gamma.-homopolymers of D-.alpha.,.gamma.-diaminobutyric acid having an average molecular weight of from about 5,100 to about 5,200. BU-2231 V has been found to be effective to inhibit growth of various Gram-positive and Gram-negative bacteria and of the herpes simplex virus.

Abstract: The actinomycete "Actinomadura sp." designated in our culture collection as Strain No. G455-101 has been deposited with the American Type Culture Collection under the Accession Number ATCC No. 31491. The taxonomic description of this microorganism is presented in detail in the specification as are instructions for fermenting aqueous nutrient media with it to produce the BBM 928 antibiotic complex. The BBM 928 complex has utility as an antibacterial agent against gram-positive and acid fast bacteria and exhibits antitumor activity against experimental animal tumors.

Abstract: A novel antibiotic complex designated herein as BBM-1675 complex is produced by fermentation of certain novel strains of Actinomadura verrucosospora. The complex may be separated into two major components, BBM-1675 A.sub.1 and A.sub.2, and four minor components, BBM-1675 A.sub.3, A.sub.4, B.sub.1 and B.sub.2, and such components exhibit both antimicrobial activity and antitumor activity.

Abstract: A novel antibiotic complex designated herein as BBM-1675 complex is produced by fermentation of certain novel strains of Actinomadura verrucosospora. The complex may be separated into two major components, BBM-1675 A.sub.1 and A.sub.2, and four minor components, BBM-1675 A.sub.3, A.sub.4, B.sub.1 and B.sub.2, and such components exhibit antimicrobial activity and also antitumor activity in certain mouse tumor systems.

Abstract: BBM-928 is a mixture of antitumor antibacterial substances produced by fermentation of Actinomadura sp., ATCC No. 31491, under controlled conditions. The components may be separated by silica gel thin layer chromatography and by other means.

Abstract: A novel antitumor antibiotic designated herein as BBM-2040 is produced by fermentation of Streptomyces sp. strain J576-99 (ATCC 39143). BBM-2040, which may be recovered from the fermentation broth in either a desmethanol (BBM-2040B) or methanol-adduct (BBM-2040A) form, inhibits gram positive and acid-fast bacteria and inhibits the growth of tumors such as P388 leukemia in mice.

Abstract: A novel antitumor antibiotic designated herein as BBM-2040 is produced by fermentation of Streptomyces sp. strain J576-99 (ATCC 39143). BBM-2040, which may be recovered from the fermentation broth in either a desmethanol (BBM-2040B) or methanol-adduct (BBM-2040A) form, inhibits gram-positive and acid-fast bacteria and inhibits the growth of tumors such as P388 leukemia in mice.

Abstract: An antitumor antibacterial complex referred to as BBM-928 is described which is produced by microbiological fermentation under controlled conditions using a species of actinomycetes. The bioactive components of the complex have pronounced antitumor activity and are moderately to weakly active against gram-positive and acid fast bacteria but practically inactive against gram-negative bacteria and fungi. Based on median survival time, the component designated BBM-928A is substantially more active than mitomycin C by a factor of 10 to 300 fold against intraperitoneally implanted mouse tumors.